GENMAB A/S -SP ADR (GMAB) Stock News

NASDAQ:GMAB - US3723032062 - ADR

27.08 USD

+1.19 (+4.6%)

Last: 9/3/2025, 8:20:13 PM

27.22 USD

+0.14 (+0.52%)

Pre-Market: 9/4/2025, 6:17:45 AM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

GMAB Latest News, Press Relases and Analysis

All

Press Releases

a day ago - By: Chartmill

News Image

GENMAB A/S -SP ADR (NASDAQ:GMAB) Meets Peter Lynch's GARP Investment Criteria

3 days ago - By: Chartmill

News Image

GENMAB A/S -SP ADR (NASDAQ:GMAB): A High-Value Biotech Play with Strong Fundamentals

a day ago - By: Genmab A/S

Genmab Announces Updated Results from Phase 2 EPCORE® NHL-6 Study Evaluating Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

6 days ago - By: Yahoo Finance - Mentions: ABBV JNJ

Genmab A/S (GMAB)’s Epcoritamab Delivers 95% Response in Lymphoma

6 days ago - By: Yahoo Finance - Mentions: PFE ABBV

Genmab A/S (GMAB) Expands Tivdak and Epkinly Commercial Push Globally

6 days ago - By: Yahoo Finance - Mentions: ACAD

ACADIA Pharmaceuticals Inc. (ACAD) Nears Phase 3 Readout in Prader-Willi Syndrome Trial

7 days ago - By: Chartmill

News Image

GENMAB A/S -SP ADR (NASDAQ:GMAB): An Affordable Growth Candidate in Biotechnology

9 days ago - By: Genmab A/S

Genmab Receives FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S®) in Advanced Endometrial Cancer (EC)

23 days ago - By: Yahoo Finance

William Blair Remains Bullish on Genmab A/S (GMAB)

a month ago - By: Benzinga - Mentions: JNJ NVS ABBV

Genmab/AbbVie Partnered Blood Cancer Combination Drug Cuts Risk Of Disease Progression By 79%

a month ago - By: Zacks Investment Research - Mentions: CRMD IOVA IMCR

IOVA Q2 Earnings Miss, Stock Down on EMA Filing Withdrawal for Amtagvi

a month ago - By: Zacks Investment Research

Wall Street Analysts Believe Genmab (GMAB) Could Rally 33.8%: Here's is How to Trade

a month ago - By: Genmab

Genmab Announces Phase 3 EPCORE® FL-1 Clinical Trial Met Dual Primary Endpoints in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL)

a month ago - By: Zacks Investment Research - Mentions: PRGO CRMD IMCR

Perrigo Beats on Q2 Earnings & Sales, Stock Down on '25 Sales View Cut

a month ago - By: Zacks Investment Research - Mentions: JAZZ CRMD IMCR

JAZZ Stock Down on Wider-Than-Expected Q2 Loss, '25 Sales View Cut

a month ago - By: Zacks Investment Research - Mentions: SIRI VRTX CRSP IMCR

CRSP Stock Down on Huge Q2 Loss, Focus on Increasing Casgevy Adoption

a month ago - By: Zacks Investment Research - Mentions: SNY BMRN IMCR

BioMarin Beats on Q2 Earnings & Sales, Stock Gains on Raised '25 View

a month ago - By: Zacks Investment Research - Mentions: SRPT ACAD

Sarepta to Report Q2 Earnings: What's in Store for the Stock?

a month ago - By: Zacks Investment Research - Mentions: TECH CRMD AMRX

Bio-Techne Q4 Earnings Preview: What's in Store for the Stock?

a month ago - By: Zacks Investment Research - Mentions: ACAD

GMAB vs. ACAD: Which Stock Is the Better Value Option?

a month ago - By: Yahoo Finance - Mentions: GS

Truist Securities Hikes Genmab A/S (GMAB) Price Target Buoyed by Revenue Outlook

2 months ago - By: Yahoo Finance - Mentions: UBS NVS JNJ

UBS Maintains a Buy on Genmab (GMAB) With a DKK2,500 PT

2 months ago - By: Yahoo Finance - Mentions: RXRX UBS RLYB

Recursion Pharmaceuticals (RXRX) Rallies 8.7% on Hypophosphatasia

3 months ago - By: Genmab

Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)

3 months ago - By: Yahoo Finance - Mentions: ABBV CSL CCK TSLA

Why Genmab Stock Smashed It on Monday

3 months ago - By: The Motley Fool

Why Genmab Stock Smashed It on Monday

3 months ago - By: Genmab A/S

Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial

3 months ago - By: Yahoo Finance - Mentions: AVGO VZ CRWD DOCU ...

Investors eye May jobs report and Trump tariff updates: What to know this week

3 months ago - By: Yahoo Finance - Mentions: SNOW ZM KODK

Genmab A/S (GMAB) Unveils Promising Rina-S and Epcoritamab Data at ASCO 2025

3 months ago - By: Genmab A/S

Genmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

4 months ago - By: Yahoo Finance - Mentions: NVDA CRWD FFIV PANW ...

CrowdStrike Strengthens AI Security with NVIDIA Enterprise AI Factory Integration

4 months ago - By: Genmab A/S

Genmab to Present New and Updated Results from its Robust Epcoritamab (EPKINLY®) Development Program at the 2025 European Hematology Association (EHA) Congress

4 months ago - By: Genmab A/S

Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)